This paper has reviewed the role of group-I PAKs in mPCa, the potential benefits of targeting PAK1 for mPCa therapy, the development and testing of ATP-competitive and allosteric inhibitors of PAK1 for cancer therapy, and compared pharmacologically targeting PAK1 with the other novel PCa therapies in development. Here, PAK1 is linked to posterior cortical atrophy.